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ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in November 2019 in China and quickly spread through-
out the world causing a disease named COVID-19. An analysis of the epidemiological data on morbidity and mortality caused by 
SARS-CoV-2 shows that, in some countries, namely Belgium, UK, France, Italy, the Netherlands, and Spain, an increased case fatal-
ity rate (CFR) was noticed compared to the rest of the world. The CFR, calculated as the number of deaths from the total number 
of the cases, ranges in these countries from 10.22% to 15.8% according to the Center for Evidence-Based Medicine (CEBM). At 
the same time, in the countries of Central and Northern Europe, this parameter varies between 3.78% and 4.94%. This significant 
heterogeneity in CFR between countries has not been given a convincing explanation yet. It was found that the precursor of SARS-
CoV-2 is a virus circulating in bats in China. The mutations that occurred in this virus altered its receptor specificity, thereby 
enabling viral infection in humans. Bats are highly resistant to viral infections due to their robust interferon system and a reduced 
level of inflammatory reactions. Viruses replicate in these animals up to high titers without any substantial harm to their health. 
As a result, bats represent a large reservoir of viruses with the potential to infect other animals, including humans. The infection 
of people with bat (or human) betacoronaviruses can lead to the formation of memory B-cells that provide an accelerated antibody 
response to cross-reactive epitopes upon subsequent infection. The early emergence of neutralizing antibodies in SARS-CoV-2 
patients correlates with the severity of the disease and the likelihood of a fatal outcome. The antibody-dependent enhancement 
(ADE) of infection/disease known for various viruses, including SARS-CoV-1 and MERS-CoV, may be a possible cause of this phe-
nomenon. In this article, we suggest a close connection between the distribution areas of bats carrying SARS-CoV-1-like viruses 
and the CFR from COVID-19.
The severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) belongs to the family Coronaviridae, sub-
family Coronavirinae, genus Betacoronavirus. Corona-
viruses are widespread among mammals and birds and 
cause respiratory, intestinal, neurological diseases as 
well as hepatitis [1]. The subfamily Coronavirinae in-
cludes 4 genera: Alfacoronavirus, Betacoronavirus, Gam-
macoronavirus, and Deltakoronavirus. The disease caused 
by SARS-CoV-2 is named COVID-19.
Coronaviruses enter the cell using the S protein, a 
glycoprotein that forms viral spikes, which are the main 
targets for neutralizing antibodies [2]. The S protein 
consists of two subunits: the variable S1, comprising a 
receptor-binding site, and the more conserved S2, which 
is responsible for the fusion of the viral and cell mem-
branes. The receptor for SARS-CoV-1 and SARS-CoV-2 
viruses is the membrane-bound angiotensin-converting 
enzyme 2 (ACE2), and for the Middle East respiratory 
syndrome coronavirus (MERS-CoV), it is the dipeptidyl 
peptidase-4 (DPP4) [3]. The affinity of SARS-CoV-2 for 
ACE2 is 10–20-fold higher than that of SARS-CoV-1 [4], 
which contributes to the increased transmissibility of the 
virus in humans.
In the majority of patients infected with SARS-CoV-2, 
the disease is asymptomatic or causes mild respiratory 
symptoms. However, almost 55% of symptomatic pa-
tients develop respiratory failure approximately by the 
eighth day of the disease, associated with bilateral multi-
lobal pneumonia [5]. In 29% of these patients, pneumo-
nia progresses to a severe stage with the development of 
a cytokine storm and acute respiratory distress syndrome 
(ARDS) often leading to a fatal outcome [5-7]. 
Like SARS-CoV-1 and MERS-CoV [8, 9], SARS-CoV-2 
infection causes increased secretion of cytokines and 
chemokines, such as interleukin-1β (IL1β), interferon-γ 
(IFNγ), IFNγ inducible protein 10 (IP10), monocyte che-
moattractant protein 1 (MCP1), IL4, and IL10. In patients 
with a more severe form of infection, requiring intensive 
therapy, high levels of IL2, IL7, IL10, granulocyte-macro-
phage colony-stimulating factor (GMCSF), IP10, MCP1, 
macrophage inflammatory protein-1α (MIP1α), and tu-
mor necrosis factor-α (TNFα) are observed in plasma 
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indicating a cytokine storm [5, 10]. Based on postmor-
tem examination of deceased patients, the virus is found 
not only in alveolar epithelial cells but also in alveolar, 
lymph node and spleen macrophages [11]. 
A correlation between the disease severity and the 
early development of an antibody response was found 
in patients during the SARS-CoV-1 outbreak in 2003. In 
patients with a severe form of the disease, who required 
additional oxygen and hospitalization in the intensive 
care unit (ICU), the antibodies emerged as early as on 
the 4th day post symptoms onset with early seroconver-
sion (<16 days) and high IgG antibody titers [12, 13]. In 
these patients, the disease outcome was more often fatal. 
In milder cases, specific antibodies emerged 2–3 weeks 
after infection, with seroconversion occurring on average 
in 20 days [13-15]. Antibody titers in asymptomatic pa-
tients were low, and seroconversions were rare.
Similarly, in patients infected with SARS-CoV-2, the 
severity of the disease was positively correlated with 
antibody titers [5]. In patients admitted to the ICU, the 
emergence of neutralizing antibodies was recorded as 
early as 5-14 days after the onset of symptoms [16].
One of the reasons for the early antibody response 
may be the presence of memory B-cells formed during 
a previous infection with antigenically related viruses. It 
is known that betacoronaviruses can induce cross-reac-
tive antibodies against each other. For instance, over the 
course of a human coronavirus OC43 infection, antibod-
ies against SARS-CoV-1 were induced and vice versa [17, 
18]. Neutralizing antibodies to the MERS-CoV virus that 
occurred in 2012 were found in the sera of patients recov-
ered from SARS-CoV-1 disease [17, 19], and neutralizing 
antibodies to SARS-CoV-2 were revealed in the sera of 
healthy donors in 3% of all cases [16].
It is known that in SARS-CoV-1 patients, antibodies 
to the S protein can enhance the pathology due to an-
tibody-dependent disease enhancement (ADE) [20]. An 
immunodominant B-cell epitope in the S protein (597-
603 aa) was mapped utilizing post-infection sera of pa-
tients recovered from SARS-CoV-1. Antibodies specific 
to this epitope elicited not only neutralizing but also 
enhancing effects on infection in non-human primates 
[21]. The ADE phenomenon is known for various viral 
infections. In the late 1960s, vaccination of children 
against respiratory syncytial virus (RSV) led to the hos-
pitalization of 80% of children with severe respiratory 
disease, with two children dying. It has been suggested 
that the cause of this disastrous vaccination result was 
the development of ADE [22, 23]. ADE is also described 
for dengue virus, influenza virus, and Ebola virus [24-
27]. 
The principle of the ADE lies in binding of the anti-S 
antibodies to the S protein on the viral surface, followed 
by docking of the immune complex to the surface of im-
munocompetent cells (monocytes, macrophages, or B-
cells) through the interaction of their Fcγ receptor (FcγR) 
with the Fc fragment of the antibodies [28]. Therefore, 
the virus can infect macrophages bypassing ACE2 recep-
tor. The interaction of neutralizing antibodies with the 
receptor-binding site of the SARS-CoV-1 S protein has 
also been reported to induce conformational change with 
the subsequent activation of the fusion protein, enabling 
the infection of macrophages and leading to transcrip-
tion of virus genome [29, 30]. Although the infection of 
macrophages does not lead to productive virus replica-
tion, their interaction with the virus causes a skew to-
wards proinflammatory M1 macrophages (Fig. 1).
Accumulation of M1 macrophages in the lungs leads 
to the increased production of chemokines, such as 
MCP1(CCL2) and IL8(CXCL8), which cause lung infiltra-
tion by proinflammatory leucocytes. As a result, there is 
a sharp increase in inflammation in the lung tissue, ac-
companied by hypercytokinemia and the development of 
ARDS [31, 32]. This process has been shown to depend on 
the concentration and affinity of anti-S antibodies. ADE 
occurred at suboptimal concentrations of antibodies or, 
in the case of their low affinity, when the virus was in-
sufficiently neutralized [33, 34]. Neutralizing anti-S anti-
bodies decreased the virus titer in macaques, at the same 
time significantly increasing pulmonary pathology [31]. 
A reduction in pathology was achieved by blocking FcγR 
[31]. Therefore, immune complexes played a key role in 
the development of ADE, and the observed organ failure 
in the cases of severe infection was caused not by exces-
sive virus replication but rather by the hyperactivation of 
the innate inflammatory response [14]. 
Fig. 1. Mechanism of the antibody-dependent enhancement of infection/disease (ADE).
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It can be assumed that over the course of the COV-
ID-19 disease ADE underlies the complications that oc-
cur in cases with an early development of the antibody 
response due to the presence of memory B-cells – poten-
tial producers of antibodies to the S protein of antigeni-
cally related coronaviruses.
Attempts to identify the host of SARS-CoV-1 in Chi-
na have shown that a closely related virus circulates in 
horseshoe bats belonging to the genus Rhinolophus, the 
family Rhinolophidae, and the order Chiroptera [35, 36]. 
The genome sequence of the first SARS-CoV-2 strains 
shares up to 86.9% sequence identity with that of the 
bat-SL-CoVZC45 coronavirus previously isolated in 
China [37]. The SARS-CoV-2 S protein shares between 
75.7% and 97.7% sequence identity with that of other bat 
coronaviruses [38, 39]. Consequently, people who come 
into contact with bats may have antibodies or memory 
B-cells that recognize SARS-CoV-2 antigens due to past 
infections with antigenically related coronaviruses that 
caused mild or asymptomatic disease.
Bats are used for food in southern China and other 
countries in this region. Live bats are commonly sold in 
markets and are used for cooking in restaurants in south-
ern China. This practice significantly facilitates the con-
tact between bats and other animals and leads to infec-
tion in humans [20]. The presence of elevated antibody 
titers to viruses close to SARS-CoV-1 in people associat-
ed with live animal markets confirms the fact that people 
are infected with viruses from bats [40]. The ADE effect 
may explain the increased number of severe COVID- 19 
cases with a fatal outcome in China among people as-
sociated with such markets [5]. After the 2002/2003 
SARS-CoV-1 outbreak, the evaluation of coronaviruses 
distribution in the world has identified bats as a natural 
reservoir of coronaviruses not only in China but also in 
Europe, America, and Australia [41]. 
Bats are the only representative of mammals capable 
of active flight. Flight is associated with enhanced cel-
lular metabolism and increased body temperature (up to 
41℃ in some bats), which increases the risk of damage to 
genomic DNA. The evolution of bats made it possible to 
prevent inflammatory reactions by weakening the cyto-
plasmic sensors of abnormal DNA and DNA pathogens, 
such as stimulators of IFN genes (STING) as well as by re-
ducing the level of inflammatory cytokine production, for 
example TNFα [42, 43]. Due to a decrease in the intensity 
of protective inflammatory responses, the sensitivity of 
bats to virus infection increased, which was compensated 
by the development of more effective antiviral measures, 
such as high constitutive expression of INF and unique 
interferon-stimulated genes (ISGs). Due to the powerful 
IFN response system and the ideal regulation of inflam-
matory responses, bats have acquired high resistance to 
viral infections [42, 43]. RNA viruses replicate in these 
animals to high titers and persist without causing sig-
nificant harm to their health. As a result, a large num-
ber of bats act as a source of viral infections in humans 
and other animals. These include dangerous infections, 
namely coronaviruses (SARS-CoV-1, MERS-CoV), filo-
viruses (Ebola and Marburg viruses), and henipaviruses 
(Hendra and Nipah viruses) [44]. The emergence of the 
SARS-CoV-2 infection in 2019 is another striking exam-
ple. Humans, who have a less sophisticated mechanism 
for inflammation control than bats, may develop a patho-
logical response of the innate immune system, such as a 
cytokine storm and ARDS.
Bats live in colonies of up to hundreds of individuals. 
Animal nests are often located in parks and in the im-
mediate vicinity of residential buildings. Bats secrete vi-
ruses with feces, in which the amount of virus can reach 
2.4x108  copies/g [45]. All species of bats in Europe are 
protected by the European Union Directive on the Con-
servation of Natural Habitats and Wild Fauna and Flora 
[46] and the Agreement on the Conservation of Popula-
tions of European Bats [47]. 
Of the four known genera of coronavirus, only two 
were found to circulate in bats: Alfacoronavirus and Beta-
coronavirus. Since 2010, alfa- and betacoronaviruses are 
constantly detected in Italian bats [48-50] and, therefore, 
in the provinces of Piedmont and Liguria, up to 26% of 
the bat colonies are infected [51]. In 13 regions of Spain, 
an examination of 576 individual bats of various species 
led to the identification of 14 new alpha- and betacoro-
naviruses [52]. In the Netherlands, betacoronaviruses 
were isolated from 211 bats, mostly of Pipistrellus genus, 
in 31 settlements. Their colonies are widely distributed 
in urban areas. The infection rate of bats with coronavi-
ruses was found to be 16.9% in the Netherlands [53] and 
37.9% in France [54]. However, the distribution of corona-
virus-carrying bats is heterogeneous. Therefore, in Ger-
many, when studying 653 bats in three regions, corona-
viruses were found much less often, only in 1.4-3.1% of 
cases [55]. The most frequently detected viruses in bats 
in Germany were astroviruses of Astroviridae family, from 
25.8% to 65%.
In many European countries, including Italy, Spain, 
France, and Bulgaria, SARS-CoV-1-like betacoronavi-
ruses were isolated exclusively from horseshoe bats of 
the genus Rhinolophus [51] as well as in China, thereby 
confirming the specificity of this host for SARS-CoV-1-
like viruses. Fig. 2 shows the distribution of Rhinolophus 
bats – carriers of SARS-CoV-1 – in the world. It is impor-
tant to note that, in addition to China and Southeast Asia, 
this genus of bats is widely represented in Southern Eu-
rope and Middle East but it is absent in Northern Europe.
When comparing the mortality rate of COVID-19 
according to the Center for Evidence-Based Medicine 
(CEBM) (Table 1) with the distribution areas of Rhinolo-
phus bats that carry SARS-CoV-1-like viruses, it is clear 
that an increased mortality from COVID-19 (with CFR 
higher than 10) [56] is observed in countries where these 
bats are widespread, such as Spain, France, Italy, the 
Netherlands, and the UK. In countries where Rhinolophus 
bats – carriers of SARS-CoV-1-like viruses – have not been 
detected, the mortality rate is significantly lower (the CFR 
is 4-6). Therefore, we assume that high CFR in COVID-19 
patients may be associated with the preexisting non-
protective immunity to related coronaviruses in people 
living in the areas that are natural habitats of infected 
bats. Among the countries of Northern Europe, Sweden 
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stands out, where no coronavirus-carrying bats have been 
detected, but a high mortality rate is observed (the CFR 
is 12). Besides the fact that Sweden was one of the few 
European countries without a lockdown, this phenome-
non could be explained by recently published information 
that, in Sweden, the majority of lethal outcomes from CO-
VID-19 are observed among immigrants from Syria, Iraq, 
and Afghanistan – the countries that are part of the distri-
bution zone of SARS-CoV-1-like virus carrying bats [57]. 
A similar situation is in the UK, where patients belonging 
to minorities groups die from coronavirus infection 27% 
more often than the general population of the UK [58]. It 
should be noted that some areas of the UK are the natu-
ral habitats of bats of the genus Rhinolophus that carry 
SARS-CoV-1-like coronaviruses. Social reasons could not 
be excluded too.
Significant differences in the CFR of COVID-19 in var-
ious countries can be explained by a number of reasons 
Fig. 2. Geographical distribution of Rhinolophus bats that carry SARS-CoV-1-like coronaviruses [41].
Table 1. Global COVID-19 Case Fatality Rates according to the Centre for Evidence-Based Medicine (April 30, 2020) [56].
Country Number of deaths Number of cases Case fatality rate, %
Belgium 7844 49906 15.72
UK 28446 186599 15.24
France 24895 168693 14.76
Italy 28884 210717 13.71
Netherlands 5056 40571 12.46
Sweden 2679 22317 12.00
Hungary 351 3035 11.57
Spain 25364 247122 10.22
Indonesia 845 11192 7.55
Slovenia 96 1439 6.67
Egypt 429 6465 6.64
Philippines 623 9485 6.57
Iran 6203 97424 6.37
USA 68602 1188421 5.77
China 4633 82880 5.59
Denmark 484 9670 5.01
Switzerland 1473 29905 4.93
Poland 683 13937 4.90
Finland 230 5254 4.38
Germany 6866 165664 4.14
Austria 598 15597 3.83
Japan 487 14877 3.27
Estonia 55 1703 3.23
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such as the BCG vaccination of population [59], vitamin D 
deficiency [60], as well as by political and social reasons. 
However, our hypothesis about the correlation between 
the population density of bats, which are a natural reser-
voir of various SARS-CoV-1-like coronaviruses, and the 
mortality rate from COVID-19 in some countries also de-
serves thorough consideration. Contact between humans 
and bats in countries with high population densities of 
the latter can lead to repeated asymptomatic infection 
during an individual’s lifetime. The likelihood of such in-
fection is low for children and young adults and increases 
with age, which is consistent with the data showing fewer 
deaths observed for patients under 20 years of age with 
the same frequency of diseases in different age groups. 
The resulting memory B-cells can lead to accelerated 
antibody production during a subsequent SARS-CoV-2 
infection. Early emergence of low-affinity antibodies in 
COVID-19 may provoke the infection of macrophages 
and hyperinflammatory response of the innate immune 
system. Therefore, the presence of immunity to corona-
viruses, gained in the course of previous infections, may 
have a damaging effect in individual patients depending 
on the presence of the memory B-cells to cross-reactive 
epitopes of antigenically related coronaviruses. The 
screening of healthy people for the presence of memory 
B-cells to SARS-CoV-2 antigens may be a way to assess 
the risk of COVID-19 severe complications.
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